Analysts expect HealthEquity (HQY) to report quarterly earnings of $1.19 per share and revenue of $350.23 million in its upcoming release, with projections indicating growth in custodial revenue and total HSA assets.
See our latest analysis for HealthEquity.
HealthEquity’s recent momentum has been firm, with a 30-day share price return of 11.38% and a 90-day share price return of 20.80%. The 1-year total shareholder return of 20.57% highlights how expectations around earnings and HSA growth are feeding into both short and longer term performance.
If you are watching how HealthEquity trades around its earnings update, it can be useful to see what else is moving in related themes, especially across 40 healthcare AI stocks.
HealthEquity now trades at a double digit discount to both analyst targets and an internal fair value estimate after a strong recent run. Is that a bargain or a sign that the market still sees real execution risk ahead?
Most Popular Narrative: 8.8% Undervalued
The most followed narrative for HealthEquity sets a fair value of $115.56 against the last close at $105.40, framing the stock as modestly undervalued and closely tied to expectations for margin expansion and HSA market growth.
Ongoing investments in fraud prevention and the transition to a fully cloud-based platform have already reduced service costs and fraud-related expenses. This progress, along with further anticipated AI-driven efficiencies, is described as setting the stage for a structurally lower cost base and margin expansion.
Want to see what sits behind that margin story? The narrative focuses on measured revenue growth, rising profitability, and a valuation multiple that reflects an assumption that those efficiencies continue to build over time. The full picture brings these elements together into one clear fair value framework.
Result: Fair Value of $115.56 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the HealthEquity narrative still hinges on two key swing factors: interest rate sensitivity around custodial cash and the risk that elevated tech spending weighs on margins if growth underwhelms.
Find out about the key risks to this HealthEquity narrative.
Another View: HealthEquity Through a P/E Lens
The fair value narrative for HealthEquity points to upside, yet the current P/E of 38.2x is well above both the US Healthcare industry at 25.5x and peers at 36.8x, and also above a fair ratio of 26.8x. That premium points to higher valuation risk if execution stumbles. Where do you place more weight?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment around HealthEquity split between opportunity and execution risk, it helps to move quickly and test the assumptions against the data yourself. To see what those optimistic factors look like in detail, review the 3 key rewards.
Looking For More Investment Ideas Beyond HealthEquity?
If you want a broader view alongside HealthEquity, use the Simply Wall Street Screener to spot other opportunities that fit your approach before the market moves.
- Target higher potential returns by scanning for quality stocks trading below their estimated value using the 49 high quality undervalued stocks.
- Prioritise resilience by checking companies that pair financial strength with dependable fundamentals through the solid balance sheet and fundamentals stocks screener (51 results).
- Seek hidden potential by reviewing the screener containing 18 high quality undiscovered gems that may not yet be widely followed but still meet strict quality filters.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com